MYOMO, INC.
Close on Oct 19, 2026
- Market cap
- $53.37M
- P/E (TTM)
- –
- Dividend yield
- –
About Myomo
Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842
Myomo is a wearable medical robotics company that develops and markets myoelectric-controlled upper limb orthoses, operating as a single business segment. Its core offering is the MyoPro product line, which includes custom-fabricated rigid arm braces that use non-invasive electromyography sensors to detect weak muscle signals and power movement in partially paralyzed upper limbs. The company serves adults and adolescents with neuromuscular conditions and upper limb paralysis resulting from stroke, brachial plexus injuries, spinal cord trauma, and other neurological disorders. Customers access these devices through direct billing to insurers, orthotics and prosthetics providers, and healthcare institutions.
The company is headquartered in Burlington, Massachusetts. It markets and distributes products across the United States, with devices ordered by more than 130 Veterans Administration facilities. Internationally, the firm holds medical device licensing in Canada, maintains European Union market authorization via CE mark compliance, and has distribution relationships with orthotics and prosthetics partners across the United Kingdom, Germany, Italy, Denmark, and Australia.
Summary of the business section of Myomo's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MYOMO, INC.
- Founded
- 2004
- Headquarters
- Boston, MA
- Address
- 137 Portland Street, 4th Floor 02114
- Phone
- (617) 996-9058
- Employees
- 184, Dec 31, 2024
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, New York, NY. USA
Stock & identifiers
- Ticker
- MYO
- Exchange
- NYSE
- IPO date
- Jun 12, 2017
- Shares outstanding
- 40M, Jul 31, 2026
- Public float
- $62.36M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-30 reverse, Mar 13, 2020; 1-for-30 reverse, Jan 31, 2020
- SEC CIK
- 1369290
- CUSIP
- 62857J201
- ISIN
- US62857J2015
- LEI
- 549300G63SSKC2EGLN41
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Paul R. Gudonis | Chief Executive Officer, Director | 1,434,679 |
| Harry Kovelman | Chief Medical Officer | 90,245 |
| Micah Mitchell | Chief Commercial Officer | 152,297 |
| David A. Henry | Chief Financial Officer | 470,163 |
| Milton Mayo Morris | Director | 208,391 |
| Heather C. Getz | Director | 210,458 |
| Joseph M. Manko Jr. | Director | 2,388,479 |
| William J. Febbo | Director | 123,704 |
| Thomas F. Kirk | Director | 772,569 |
| Thomas Aloysius Crowley Jr. | Director | 154,931 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Paul Gudonis | $1.20M | -$348.55K | $649.02K | $178 | – |
| FY2024 Paul Gudonis | $1.24M | $1.51M | $739.64K | $1259 | – |
| FY2023 Paul Gudonis | $663.90K | $2.12M | $478.64K | $980 | – |
| FY2022 Paul Gudonis | $526.04K | $179.60K | $352.85K | $7 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2024, we employed a total of 184 full time employees and 1 part time employee.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 10, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jun 8, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |